Hutchmed (China) (00013.HK) announced that the SAVANNAH Phase II study has achieved positive topline results, showing a high, clinically meaningful and durable improvement in objective response rate (ORR) in patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations, who have had disease progression after prior treatment with Tagrisso (osimertinib) and have high levels of MET amplification and/or overexpression (defined as IHC90+ and/or FISH10+), when treated with a combination therapy of Tagrisso and Orpathys (savolitinib). The data will be presented at an upcoming scientific meeting and shared with global regulatory institutions.

Orpathys is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) jointly developed by AstraZeneca (AZN.US) and Hutchmed (China), with AstraZeneca being responsible for commercialization. It has been approved in China for the treatment of non-small cell lung cancer patients with MET exon 14 skipping mutations who have experienced disease progression after systemic therapy or are ineligible for chemotherapy.